Home » Stocks » Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. (RYTM)

Stock Price: $22.62 USD -1.47 (-6.10%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 997.96M
Revenue (ttm) n/a
Net Income (ttm) -134.24M
Shares Out 44.12M
EPS (ttm) -3.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $22.62
Previous Close $24.09
Change ($) -1.47
Change (%) -6.10%
Day's Open 24.46
Day's Range 22.52 - 24.46
Day's Volume 149,181
52-Week Range 12.99 - 32.24

More Stats

Market Cap 997.96M
Enterprise Value 772.26M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 44.12M
Float 35.26M
EPS (basic) -3.26
EPS (diluted) -3.26
FCF / Share -2.99
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.01M
Short Ratio 4.81
Short % of Float 5.71%
Beta 1.29
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.71
Revenue n/a
Operating Income -138.55M
Net Income -134.24M
Free Cash Flow -131.91M
Net Cash 225.70M
Net Cash / Share 5.12
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -37.15%
ROE -65.93%
ROIC -78.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

(45.36% upside)
Current: $22.62
Target: 32.88
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-146-78.42-32.41-25.91-10.57
Net Income-141-74.06-37.58-25.87-11.07
Shares Outstanding36.4231.0013.2710.2010.20
Earnings Per Share-3.86-2.39-2.83-2.85-1.18
Operating Cash Flow-123-62.06-29.46-23.22-6.75
Capital Expenditures-3.39-0.72-0.13-1.06-0.02
Free Cash Flow-126-62.78-29.59-24.28-6.77
Cash & Equivalents29325214810.7635.09
Total Debt3.56----
Net Cash / Debt28925214810.7635.09
Book Value281246145-32.70-8.00
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Rhythm Pharmaceuticals, Inc.
Country United States
Employees 70
CEO David P. Meeker

Stock Information

Ticker Symbol RYTM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RYTM
IPO Date October 5, 2017


Rhythm Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.